A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

NCT07196774 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

740

Enrollment

INDUSTRY

Sponsor class

Conditions

Early-stage or Locally Advanced HER2-positive Breast Cancer

Interventions

DRUG: SHR-A1811 for Injection
DRUG: Docetaxel injection
DRUG: Trastuzumab Injection
DRUG: Carboplatin for Injection
DRUG: Pertuzumab Injection

Sponsor

Jiangsu HengRui Medicine Co., Ltd.